Search research articles
Contact Us
Filters
Showing results (91-100 of 111) with videos related to
Page
of 12
Sort By:
Cancers
|
November 27, 2021
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
Constantinos Zamboglou, Simon K B Spohn, Sonja Adebahr, et al.
Radiation Oncology (London, England)
|
September 23, 2018
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
Nicole Wiedenmann, Hatice Bunea, Hans C Rischke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 17, 2015
Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process
Ursula Nestle, Hans Christian Rischke, Susanne Martina Eschmann, et al.
Radiation Oncology (London, England)
|
August 31, 2018
Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
Nicole Wiedenmann, Hatice Bunea, Hans C Rischke, et al.
Radiation Oncology (London, England)
|
August 7, 2024
The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks on <sup>18</sup>F-PSMA-1007 PET
Julius C Holzschuh, Michael Mix, Martin T Freitag, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 18, 2020
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [<sup>68</sup>Ga]PSMA-PET-guided metastasis-directed therapy
Marco M E Vogel, Stephanie G C Kroeze, Christoph Henkenberens, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 17, 2025
Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01)
Simon K B Spohn, Constantinos Zamboglou, Sophia L Bürkle, et al.
European Urology Focus
|
September 10, 2019
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation
Stephanie G C Kroeze, Christoph Henkenberens, Nina Sophie Schmidt-Hegemann, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 2, 2023
Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer
Julius C Holzschuh, Michael Mix, Juri Ruf, et al.
BMC Cancer
|
May 1, 2020
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
Ann-Kathrin Oehus, Stephanie G C Kroeze, Nina-Sophie Schmidt-Hegemann, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 111) with videos related to
Sort By:
Page
of 12
Cancers
|
November 27, 2021
PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial
Constantinos Zamboglou, Simon K B Spohn, Sonja Adebahr, et al.
Radiation Oncology (London, England)
|
September 23, 2018
Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
Nicole Wiedenmann, Hatice Bunea, Hans C Rischke, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 17, 2015
Improved inter-observer agreement of an expert review panel in an oncology treatment trial--Insights from a structured interventional process
Ursula Nestle, Hans Christian Rischke, Susanne Martina Eschmann, et al.
Radiation Oncology (London, England)
|
August 31, 2018
Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
Nicole Wiedenmann, Hatice Bunea, Hans C Rischke, et al.
Radiation Oncology (London, England)
|
August 7, 2024
The impact of multicentric datasets for the automated tumor delineation in primary prostate cancer using convolutional neural networks on <sup>18</sup>F-PSMA-1007 PET
Julius C Holzschuh, Michael Mix, Martin T Freitag, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
March 18, 2020
Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [<sup>68</sup>Ga]PSMA-PET-guided metastasis-directed therapy
Marco M E Vogel, Stephanie G C Kroeze, Christoph Henkenberens, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
April 17, 2025
Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01)
Simon K B Spohn, Constantinos Zamboglou, Sophia L Bürkle, et al.
European Urology Focus
|
September 10, 2019
Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation
Stephanie G C Kroeze, Christoph Henkenberens, Nina Sophie Schmidt-Hegemann, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 2, 2023
Deep learning based automated delineation of the intraprostatic gross tumour volume in PSMA-PET for patients with primary prostate cancer
Julius C Holzschuh, Michael Mix, Juri Ruf, et al.
BMC Cancer
|
May 1, 2020
Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
Ann-Kathrin Oehus, Stephanie G C Kroeze, Nina-Sophie Schmidt-Hegemann, et al.
Page
of 12